




>>Entry Name: Clevudine, INN, USAN

Synonym(s): 1-(2-Deoxy-2-fluoroarabinofuranosyl)-5-methyl-2,4(1*H*,3*H*)-pyrimidinedione, 9Cl. 1-(2-Deoxy-2-fluoroarabinofuranosyl)thymine. 2'-Fluoro-5-methylarabinofuranosyluracil. FMAU



Related CAS Registry Numbers(s): 97672-34-9 172494-45-0

Molecular Formula: C₁₀H₁₃FN₂O₅

Molecular Weight: 260.222

Accurate Mass: 260.080851

Percentage Composition: C 46.16%; H 5.04%; F 7.30%; N 10.77%; O 30.74%

General Statement: Strictly, the name Clevudine refers to the β -L-form

Biological Use/Importance: Antiviral agent for hepatitis B virus and Epstein-Barr virus

>>Variant: β -D-form

Synonym(s): β -FMAU. D-FMAU

CAS Registry Number: 69256-17-3

Molecular Formula: C₁₀H₁₃FN₂O₅

Molecular Weight: 260.222

Accurate Mass: 260.080851

Percentage Composition: C 46.16%; H 5.04%; F 7.30%; N 10.77%; O 30.74%

Biological Use/Importance: Antiviral agent with antineoplastic activity *in vitro*

Physical Description: Cryst. (H₂O)

Development Status: Clin. trial discontinued due to neurotoxic effects

Melting Point: Mp 187-188°

>>Variant: β -L-form

Synonym(s): L-FMAU

CAS Registry Number: 163252-36-6

Molecular Formula: C₁₀H₁₃FN₂O₅

Molecular Weight: 260.222

Accurate Mass: 260.080851

Percentage Composition: C 46.16%; H 5.04%; F 7.30%; N 10.77%; O 30.74%

Physical Description: Cryst. (MeOH/CHCl₃)

Melting Point: Mp 184-185°

Optical Rotation: $[\alpha]_D^{25} -111.77$ (c, 0.23 in MeOH)

References:

- Watanabe, K.A. *et al.*, *J. Med. Chem.*, 1979, **22**, 21-24; 1983, **26**, 152-156, (β -D-form, synth, biochem)
- Philips, F.S. *et al.*, *Cancer Res.*, 1983, **43**, 3619-3627, (β -D-form, pharmacol)
- Feinberg, A. *et al.*, *Drug Metab. Dispos.*, 1984, **12**, 784-786, (β -D-form, metab)
- Tann, C.H. *et al.*, *J.O.C.*, 1986, **50**, 3644-3647, (β -D-form, synth, ir, pmr)
- Chou, T.C. *et al.*, *Antimicrob. Agents Chemother.*, 1987, **31**, 1355-1358, (β -D-form, biochem)
- Abbruzzese, J.L. *et al.*, *Invest. New Drugs*, 1989, **7**, 195-201, (β -D-form, use, tox)
- Watanabe, K.A. *et al.*, *Carbohydr. Res.*, 1991, **216**, 1-9, (β -D-form, pmr)
- Chu, C.K. *et al.*, *Antimicrob. Agents Chemother.*, 1995, **39**, 979-981, (synth, activity, clevudine)
- Pat. Coop. Treaty (WIPO), 1995, Univ. of Georgia Res. Found., 95 20 595; CA, **124**, 56575n, (synth, pharmacol)
- Yao, G.-Q. *et al.*, *Biochem. Pharmacol.*, 1996, **51**, 941-947, (pharmacol)
- Wright, J.D. *et al.*, *Biopharm. Drug Dispos.*, 1996, **17**, 197-207, (pharmacokinetic)
- Ma, T. *et al.*, *J. Med. Chem.*, 1996, **39**, 2835-2843, (synth, pmr, uv, pharmacol)
- Aguesse-Germon, S. *et al.*, *Antimicrob. Agents Chemother.*, 1998, **42**, 369-376, (activity)
- Liu, S.-H. *et al.*, *Antimicrob. Agents Chemother.*, 1998, **42**, 833-839, (pharmacol)
- Chu, C.K. *et al.*, *Drugs of the Future*, 1998, **23**, 821-826, (rev)